Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Report 2021
SKU ID : QYR-17499353 | Publishing Date : 03-Mar-2021 | No. of pages : 137
Market Analysis and Insights: Global Gastrointestinal Stromal Tumor (GIST) Drug Market
The global Gastrointestinal Stromal Tumor (GIST) Drug market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.
Global Gastrointestinal Stromal Tumor (GIST) Drug Scope and Market Size
The global Gastrointestinal Stromal Tumor (GIST) Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gastrointestinal Stromal Tumor (GIST) Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Amcasertib
Anagrelide hydrochloride CR
APG-1351
Binimetinib
Others
Segment by Application
Clinic
Hospital
Others
The Gastrointestinal Stromal Tumor (GIST) Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Gastrointestinal Stromal Tumor (GIST) Drug market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Natco Pharma Limited
Nerviano Medical Sciences S.r.l.
Novartis AG
Omeros Corporation
The global Gastrointestinal Stromal Tumor (GIST) Drug market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.
Global Gastrointestinal Stromal Tumor (GIST) Drug Scope and Market Size
The global Gastrointestinal Stromal Tumor (GIST) Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gastrointestinal Stromal Tumor (GIST) Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Amcasertib
Anagrelide hydrochloride CR
APG-1351
Binimetinib
Others
Segment by Application
Clinic
Hospital
Others
The Gastrointestinal Stromal Tumor (GIST) Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Gastrointestinal Stromal Tumor (GIST) Drug market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Natco Pharma Limited
Nerviano Medical Sciences S.r.l.
Novartis AG
Omeros Corporation
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.